Defence Therapeutics Inc. received the Best Poster Award at World ADC San Diego 2026 for its innovative Accum®-ADC research and led a main-stage discussion on intracellular delivery in antibody-drug conjugates (ADCs). This recognition highlights the growing impact of Defence's Accum® platform in advancing next-generation cancer therapies. The company also strengthened partnerships with pharma and biotech firms to further develop and commercialize its technology, aiming to improve cancer treatment efficacy and safety.
Defence Therapeutics' recent recognition at World ADC San Diego 2026 provides context for readers interested in health-sector market activity. As of Oct 19, 2026 13:41 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 87 advanced while 59 declined. Notable movers include MESO at USD 12.69 with a -7.98% change, INCY at USD 103.10 down 7.59%, and TVTX at USD 49.60 down 6.89%, with MESO showing a typical hold time of 16 days on Pluang.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
